TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05974553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy for Justice-Involved Veterans
Description: 16 weeks of Dialectical Behavior Therapy for Justice-Involved Veterans, including weekly 60-minute group therapy and biweekly 30-minute individual case management
Study: NCT06487351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The adapted PHBI
Description: The adapted intervention is expected to be an online 60-minute video with an educational part about implicit racial bias, its consequences in healthcare inequalities, how to mitigate it, and seven case scenarios (5 minutes each) to train pharmacy interns on aspects related to cultural competency and how and when to use IBMS to reduce the impact of bias on prescribing PrEP for people of color.
Study: NCT05974553

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Group Psychotherapy for Justice-Involved Veterans
Description: 16 weeks of clinician-facilitated supportive group psychotherapy for justice-involved Veterans, including weekly 75-minute group psychotherapy (20 hours total intervention). All interventions delivered via telehealth.
Study: NCT06487351

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The NIH Implicit Bias course
Description: The NIH Implicit Bias course consists of three modules designed to teach users what bias is, how to recognize it, and how to minimize its impact
Study: NCT06637176

Intervention type: DEVICE
Intervention: Laser speckle contrast imaging
Description: LSCI measurements will be taken before and after the formation of the anastomosis, with the surgeon blinded to the measurements to prevent any influence on surgical decision-making. The surgery will be performed as standard-of-care, unaffected by the LSCI measurements.~Following the surgery, the LSCI images will be presented to the surgeon, who will complete a questionnaire assessing whether the LSCI images, if presented perioperatively, would have influenced their decision regarding the location of the anastomotic site. Additionally, the surgeon will be asked if they consider LSCI to be a useful intraoperative tool in general. The surgical case and the series of LSCI images will also be presented to an independent surgeon, who will answer the same set of questions.~The LSCI measurements will be correlated with 30-day complication rates, with a specific focus on anastomotic leakage (AL).~Microcirculation is assessed using LSCI at a wavelength of 785 nm (MoorFLPI-2, Moor Instruments
Study: NCT04942197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: use pregnancy management application
Description: Pregnant women who used pregnancy management application, which tells patients what she need to know during pregnancy, when to perform tests, and what precautions to take for your baby.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: use pregnancy management application
Description: Pregnant women who used pregnancy management application, which tells patients what she need to know during pregnancy, when to perform tests, and what precautions to take for your baby.
Study: NCT04591015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital: DD-CA
Description: In the DD-CA group, participants will be offered a proven digital texting platform in their language of preference (Spanish/English) as part of the diabetes transitions discharge program with educational, motivational and medication adherence messaging that is currently an arm of our parent DD-ME grant with added COVID support messages that provide information addressing identified barriers in Hispanic underserved communities (e.g. obtaining testing supplies and medications, accessing routine medical care, and completing other important diabetes self-management behaviors such as healthful eating, exercise, social distancing, quarantine, and stay-at-home/lockdown guidelines).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hospital: Usual Care (UC)
Description: In the UC group, participants will not receive the added COVID support messages, both groups will have a referral placed to the Diabetes Transitions Service (DTS) at the time of discharge as part of usual care. Participants will be contacted by a peer health coach following protocol to coordinate care with outpatient health and other community resources.
Study: NCT05134818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: observer tool
Description: comparison of the efficacy of an observer tool to enhance learning of technical skills of CVC insertion in anesthesiology residents The resident will complete an observer tool each time another resident is observed to insert a CVC on the simulator.
Study: NCT05721313

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root resection
Description: It will be carried out under local anestesia. Intra-crevicular or para-marginal gingival incision will be carried out and full-tickness mucoperiostal flaps will be raised to expose the affected roots. Whit the use (if possible) of a surgical stent an incision will be performed on the root to be removed. Biodentine will be used for retrogade obturation. The flaps will be sutured.
Study: NCT06237881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSQ-001EX
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSQ-001EX
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSQ-001EX
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV
Study: NCT05080491

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: immuno analysis and neuropsychological tests
Description: A venous blood sample will be taken for assay in immuno-analysis including and for assay in chromatography with mass spectrometry. Patients will participate in computer neuropsychological tests: .~Venous blood collection and the administration : the tubes are transported to the biochemistry laboratory of the University Hospital Center of Nice (CHU Nice) which prepares five aliquots (4 for assays in immuno-analysis including 2 on site, and one for assay in chromatography with mass spectrometry.~Administration of two neuropsychological tests on computer(Attention Network Task and Tower of London).
Study: NCT05360264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine 50 MG [Dacogen]
Description: DACOGEN will be administered i.v. over 1 hour, at the dose of 10 mg/m2/d, daily on days 1-5 and 8-12 of each 4-wk cycle.
Study: NCT05311865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Club event
Description: Participate in a club event without a mask, indoors, with vaccinated people.
Study: NCT05036473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WD-1603 Carbidopa-Levodopa Extended-Release Tablets
Description: Taking WD-1603 tablets or placebo orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours (±30 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WD-1603 Carbidopa-Levodopa Extended-Release Tablets
Description: Taking WD-1603 tablets or placebo orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours (±30 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WD-1603 Carbidopa-Levodopa Extended-Release Tablets
Description: Taking WD-1603 tablets or placebo orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours (±30 minutes).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets-matching the active groups.
Study: NCT05441332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EOS Radiation
Description: One EOS exam of lower extremities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semi-structured interview
Description: Semi-structured interview to identify factors influencing patient adherence behavior for a sub-group of 15 patients. By phone, between 1 to 3 months after inclusion.
Study: NCT06252077

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: very low ketogenic diet
Description: 1 month of active phase of very low ketogenic diet
Study: NCT06237881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given by IV
Study: NCT05140187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV-TCR-T cells
Description: The patients with CMV infection after HSCT will receive one to three doses of donor-derived CMV-TCR-T cells, with the escalated doses including 1×10\^3/kg, 1×10\^5/kg, and 5×10\^5/kg CMV-TCR-T cells per dose.
Study: NCT06238401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACR246 for injection
Description: 80 mg/vial
Study: NCT04969835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVA6000
Description: AVA6000 is a FAP-activated doxorubicin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVA6000
Description: AVA6000 is a FAP-activated doxorubicin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVA6000
Description: AVA6000 is a FAP-activated doxorubicin.
Study: NCT06340919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sudden Sound Reduction Setting
Description: Each participant will listen to recordings of sentences processed by a hearing aid with settings for treating sudden sounds set to Low, High, or Maximum. Recordings with the different settings will be randomized from trial to trial.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sudden Sound Reduction Setting
Description: Each participant will listen to recordings of sentences processed by a hearing aid with settings for treating sudden sounds set to Low, High, or Maximum. Recordings with the different settings will be randomized from trial to trial.
Study: NCT05913375

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Non-invasive delivery of ablative radiotherapy dose to the arrhythmia substrate defined with electroanatomical mapping (EAM)
Study: NCT06340919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sudden Sound Reduction Setting
Description: Each participant will listen to recordings of sentences processed by a hearing aid with settings for treating sudden sounds set to Low, High, or Maximum. Recordings with the different settings will be randomized from trial to trial.
Study: NCT06383494

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA supreme group
Description: Patient in this group received LMA supreme (one of laryngeal airway management device) for airway management during general anesthesia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel group
Description: Patient in this group received I-gel laryngeal (one of laryngeal airway management device) for airway management during general anesthesia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GMA-Tulip
Description: Patient in this group received GMA-Tulip (one of laryngeal airway management device) for airway management during general anesthesia
Study: NCT04908995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC5026 oral tablet
Description: 12 subjects will receive a single oral 8 mg dose of EC5026 in two Dosing Periods (one in fed state and one in fasted state) separated by a Washout Period. Subjects in this group will be randomized 1:1 to one of 2 sequences:~* Dosing Sequence A: Subjects will be dosed in a fed state in Dosing Period 1 and in a fasted state in Dosing Period 2, or~* Dosing Sequence B: subjects will be dosed in a fasted state in Dosing Period 1 and in a fed state in Dosing Period 2.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 6 subjects will receive an oral dose of matching placebo in one single Dosing Period. Subjects in this group will be randomized 1:1 to receive placebo under fed or fasted conditions.~Note: Subjects assigned to the placebo arm will not return for a second Dosing Period.
Study: NCT06047704

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05946343

Intervention type: DIAGNOSTIC_TEST
Intervention: Surface Electromyography (sEMG) Assessment
Description: Surface electromyography (sEMG) will be used to assess the activation patterns of scapular and rotator cuff muscles during functional tasks, such as shoulder flexion, abduction, and external rotation. The sEMG assessment will be conducted using a wireless sEMG system with a sampling rate of 2000 Hz and a bandwidth of 20-500 Hz. Pre-gelled, disposable, self-adhesive Ag/AgCl electrodes will be placed on the muscle belly according to SENIAM guidelines, with an inter-electrode distance of 20 mm.

Intervention type: DIAGNOSTIC_TEST
Intervention: Surface Electromyography (sEMG) Assessment
Description: Surface electromyography (sEMG) will be used to assess the activation patterns of scapular and rotator cuff muscles during functional tasks, such as shoulder flexion, abduction, and external rotation. The sEMG assessment will be conducted using a wireless sEMG system with a sampling rate of 2000 Hz and a bandwidth of 20-500 Hz. Pre-gelled, disposable, self-adhesive Ag/AgCl electrodes will be placed on the muscle belly according to SENIAM guidelines, with an inter-electrode distance of 20 mm.
Study: NCT06475469

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling & Chest CT without injection
Description: Anlaysis of the repartition of non-tumorous lymphocytic subpopulation in patients with untreated Chronic Lymphocytic Leukemia (CLL)
Study: NCT05838326

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Symmetrical high flow nasal cannula (HFNO)
Description: After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a PaO2/FiO2 ratio \< 300, patients will be randomly assigned to a first 1h-phase of 'conventional HFNO' or 'DUET HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60 L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain SpO2 between 92 and 98%.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Asymmetrical high flow nasal cannula (DUET HFNO)
Description: After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a PaO2/FiO2 ratio \< 300, patients will be randomly assigned to a first 1h-phase of 'DUET HFNO' vs 'conventional HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60 L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain SpO2 between 92 and 98%.~A 5-10min 'washout' phase using VM, between different interfaces, will be allowed.
Study: NCT05106153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Suvorexant will be administered orally as per assigned treatment sequence.
Study: NCT05663970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VG Social ABCs
Description: The Social ABCs is an evidence-based caregiver-mediated early intervention. This trial examines the 6-week Virtual Group Social ABCs; an adapted model of the existing evidence-based Social ABCs. The targets are functional directed vocalizations and positive emotion sharing with a caregiver. It is provided to small groups of parents (4-8 per group) who meet virtually for a series of 6 didactic learning sessions led by two trained Coaches, supported by the programs Parent Manual, PowerPoint slides, facilitated discussion, reflection, and idea generation. Each family is assigned a Coach, and one parent per family receives 9 individualized, 1:1 live coaching sessions over a 6-week period via the virtual platform with the goal of learning to implement the Social ABCs strategies with their child. 10-min video recordings of caregiver and child are taken at baseline(time 0), post intervention (time 1),and follow up (time 2) as a measurement of fidelity of implementation and child responsivity.
Study: NCT05106153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Suvorexant will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Suvorexant will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Suvorexant will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Suvorexant will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Suvorexant will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Suvorexant will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Suvorexant will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Suvorexant will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Suvorexant will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Suvorexant will be administered orally as per assigned treatment sequence.
Study: NCT05707208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-01
Description: A sustained release lidocaine formulation designed for the treatment of acute and chronic pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-01
Description: A sustained release lidocaine formulation designed for the treatment of acute and chronic pain.
Study: NCT05707208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Lidocaine HCL
Description: Currently approved lidocaine
Study: NCT06422182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain 25% (Erector Spinae Plane Block)
Description: Patients received ultrasound guided bilateral single shot erector spinae pane block (ESPB) at Th10 level with 20 mL 0.25% bupivacaine after the end of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine (Intravenous patient-controlled analgesia)
Description: Patients received intravenous patient-controlled analgesia (IV-PCA) by morphine
Study: NCT05922202

Intervention type: OTHER
Intervention: Assessment of cardiovascular events, cardiovascular mortality, all-cause mortality, and mortality due to COPD at 12 and 24 months
Description: At 12 and 24 months of follow up, cardiovascular events (including hospital admissions), deaths due to cardiovascular disease, deaths due to all-cause, deaths due to COPD will be recorded in COPD outpatients group.
Study: NCT04939857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Description: The experimental group will be treated with trimetazidine, and the control group will not be intervened
Study: NCT05532397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QPOP category 1
Description: combination regimens with published data in the setting of gliomas

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QPOP category 2
Description: combination regimens where there is published data on intracranial activity and anti-glioma effect of the individual agents either as monotherapy or in combination with other agents, and where there is published safety data on the combination
Study: NCT05527951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eMBC
Description: The experimental group will implement eMBC with our WeChat Easy to Recover from Depression Mini-Program, which consists of mood tracking and lay-coached self-management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard MBC
Description: The control intervention group will implement standard MBC using paper and pencil questionnaires.
Study: NCT06070428

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PAC provision at hospital discharge
Description: Patients randomized to receive the intervention will receive two PACs fitted with True HEPA filters.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control non-intervention; PAC without filter
Description: Patients randomized to the control non-interventional arm will receive two PACs with no filters inserted.
Study: NCT05106153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally as per assigned treatment sequence.
Study: NCT05093790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Specified dose on specified days
Study: NCT05304091

Intervention type: OTHER
Intervention: Questionnaire on a smartphone application
Description: Each day, the smartphone application will ask the patient if he or she is having an angioedema attack. It not, the questionnaire will stop. If the patient is having an attack, a series of 5 short questions is asked about the attack characteristics and the events that preceded it.